Ratings Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
57.6 ^USD	-1.10%		+0.88%	+44.87%

08/05	Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000	MT
19/03	Morphic Holding Names Simon Cooper as Chief Medical Officer	MT

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
KEROS THERAPEUTICS, INC.	+44.87%	2.1B	C-
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B	B+
REGENERON PHARMACEUTICALS, INC.	+10.21%	105B	B+
ARGENX SE	+1.57%	23.46B	B
BIONTECH SE	-12.77%	21.72B	B+
GENMAB A/S	-7.05%	18.64B	A-
WUXI APPTEC CO., LTD.	-37.64%	17.45B	A-
BEIGENE, LTD.	-6.50%	17.19B	B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	13.99B	C+
SAREPTA THERAPEUTICS, INC.	+37.20%	12.53B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes